Opdivo® (nivolumab) has been approved by the European Commission for gastric, gastroesophageal junction (GEJ), or oesophageal adenocarcinoma.
List view / Grid view
According to a new study, Drug Ranking Using Machine Learning (DRUML) can accurately rank cancer therapies by efficacy across a range of cancer types.
Researchers at NYU Langone Health's Perlmutter Cancer Center report that at least three kinds of bacteria in the mouths of Americans may directly affect their risk of developing oesophageal cancer.
Proton beam therapy, in combination with chemotherapy, may be a better treatment option than traditional radiation therapy techniques...
Brazilian researchers have investigated whether cisplatin and 5-FU would interfere with the protein pRB...